The current study confirms that IDegAsp administered OD before breakfast is non-inferior to IGlar OD in terms of reducing HbA1c levels from baseline to 26 and 52 weeks in insulin-naïve T2DM patients inadequately controlled on metformin. This evidence concerns the gene INS and type 2 diabetes mellitus.